Get the Stockscreener App
110.11
1.80%
-2.005
Sarepta Therapeutics Inc stock is traded at $110.11, with a volume of 343.78K.
It is down -1.80% in the last 24 hours and down -11.57% over the past month.
See More
Previous Close:
$112.11
Open:
$112
24h Volume:
343.78K
Relative Volume:
0.37
Market Cap:
$11.66B
Revenue:
$1.64B
Net Income/Loss:
$121.85M
P/E Ratio:
71.50
EPS:
1.54
Net Cash Flow:
$-480.40M
1W Performance:
-3.19%
1M Performance:
-11.57%
6M Performance:
-21.40%
1Y Performance:
-12.66%
1-Day Range:
$110.01
$112.37
1-Week Range:
$110.01
$120.05
52-Week Range:
$102.16
$173.25
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Name
Sarepta Therapeutics Inc
Sector
Industry
Phone
617-274-4000
Address
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
110.09 | 11.66B | 1.64B | 121.85M | -480.40M | 1.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.53 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.11 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.43 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.00 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.70 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-27-24 | Reiterated | Needham | Buy |
| Nov-25-24 | Initiated | H.C. Wainwright | Sell |
| Nov-07-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jul-29-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-26-24 | Downgrade | Citigroup | Buy → Neutral |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| May-28-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-14-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-13-23 | Resumed | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-21-23 | Initiated | Wedbush | Outperform |
| Oct-31-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-31-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-23-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-04-23 | Initiated | Citigroup | Buy |
| Mar-01-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-22-22 | Reiterated | BTIG Research | Buy |
| Dec-16-22 | Upgrade | UBS | Neutral → Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-05-22 | Reiterated | Needham | Buy |
| Dec-09-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-21 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Jan-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-11-21 | Downgrade | UBS | Buy → Neutral |
| Jan-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Jan-08-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-31-20 | Initiated | Mizuho | Buy |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Aug-21-19 | Reiterated | Needham | Buy |
| Jul-09-19 | Reiterated | Morgan Stanley | Overweight |
| Jul-01-19 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-11-19 | Reiterated | Credit Suisse | Outperform |
| Oct-12-18 | Initiated | Bernstein | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-26-18 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-14-18 | Resumed | BofA/Merrill | Buy |
| Sep-06-18 | Initiated | Credit Suisse | Outperform |
| Aug-01-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-21-18 | Reiterated | Robert W. Baird | Outperform |
| Jun-20-18 | Reiterated | Needham | Buy |
| Jun-19-18 | Reiterated | H.C. Wainwright | Buy |
View All
Sarepta Therapeutics Inc Stock (SRPT) Latest News
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by abrdn plc - MarketBeat
Nvidia And 2 Other High Growth Tech Stocks In The United States - Simply Wall St
Zacks Research Has Positive Estimate for SRPT Q4 Earnings - MarketBeat
Cell and Gene Therapy Market to Witness Massive Growth - openPR
Yorktown Management & Research Co Inc Invests $559,000 in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
FY2024 Earnings Estimate for SRPT Issued By Zacks Research - MarketBeat
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Delivered A Weaker ROE Than Its Industry - Yahoo Finance
Exosome Diagnostics & Therapeutics Market to Grow by USD 1.01 Billion (2025-2029) with Rising Research in Exosome Therapeutics Boosting the Market, Report on How AI is Driving Market TransformationTechnavio - The Malaysian Reserve
Duchenne Muscular Dystrophy Market Report 2034: Epidemiology - openPR
Swedbank AB Buys Shares of 137,400 Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates? - Yahoo Finance
Q4 Earnings Estimate for SRPT Issued By William Blair - MarketBeat
Sarepta Therapeutics’ (SRPT) Sell Rating Reiterated at HC Wainwright - Defense World
Sivik Global Healthcare LLC Acquires Shares of 10,000 Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Given "Sell" Rating at HC Wainwright - MarketBeat
Jim Cramer Says ‘I Think Sarepta Therapeutics, Inc. (SRPT) Is A Speculative Situation Where They Have Great Science’ - Insider Monkey
Nisa Investment Advisors LLC Buys 247 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World
Equities Analysts Set Expectations for SRPT Q4 Earnings - Defense World
Mucopolysaccharidosis Type III Pipeline 2024: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Takeda Pharma, BioMarin Pharma, Ultragenyx Pharma, Sarepta - Barchart
BMO maintains Outperform on Sarepta stock, $200 target - MSN
Sarepta could be down on patient death in FDA database, says RBC Capital - Yahoo Finance
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Arrowhead Pharma Stock Soars Pre-Market On $825M Sarepta Licensing Deal: Retail Activity Hits Year-High - MSN
Cancer Gene Therapy Market Outlook 2025-2032: Witness Booming - openPR
Sarepta’s DMD Gene Therapy Elevidys Shows Sustained Benefit in Updated Phase 3 Data - CGTLive™
Mizuho maintains Sarepta stock with $195 target on trial data - MSN
Neuromuscular Disease Therapeutics Market to grow by USD 13.73 Billion (2025-2029), novel approvals for neuromuscular treatments boost growth, AI-powered market evolutionTechnavio - The Malaysian Reserve
Sarepta Therapeutics' SWOT analysis: gene therapy leader's stock faces pivotal year - MSN
Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
Roche reports positive topline outcomes from DMD treatment trial - Yahoo Finance
Sarepta Therapeutics (NASDAQ:SRPT) Given Buy Rating at Needham & Company LLC - Defense World
Sarepta buoyed by additional phase 3 data for Duchenne treatment Elevidys - MSN
Morgan Stanley maintains $200 target on Sarepta Therapeutics stock - MSN
Needham & Company LLC Reaffirms Buy Rating for Sarepta Therapeutics (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years - Benzinga
Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS - BioSpace
Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD) - Roche
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Brokerages Set Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Target Price at $178.71 - MarketBeat
William Blair Issues Optimistic Estimate for SRPT Earnings - MarketBeat
Mucopolysaccharidosis (MPS) Treatment Market Growth in Future - openPR
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory - MSN
Duchenne Muscular Dystrophy Clinical and Non-Clinical - openPR
Leerink Partnrs Issues Optimistic Estimate for SRPT Earnings - MarketBeat
These 4 Measures Indicate That Sarepta Therapeutics (NASDAQ:SRPT) Is Using Debt Reasonably Well - Simply Wall St
Smith Salley Wealth Management Buys Shares of 7,308 Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Biogen, Sarepta Quick Drug Approvals Show FDA Gaps, Report Says - MSN
Assenagon Asset Management S.A. Sells 217,594 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Undercovered Dozen: Lincoln National, Whitecap Resources, NMI Holdings, Healwell AI + - Seeking Alpha
What is HC Wainwright's Forecast for SRPT FY2024 Earnings? - MarketBeat
Sarepta Therapeutics Inc Stock (SRPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sarepta Therapeutics Inc Stock (SRPT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wigzell Hans Lennart Rudolf | Director |
Dec 12 '24 |
Option Exercise |
13.71 |
10,500 |
143,955 |
33,340 |
| Wigzell Hans Lennart Rudolf | Director |
Dec 12 '24 |
Sale |
124.84 |
10,500 |
1,310,820 |
22,840 |
0.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):